Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy

Houben, Isabeau; Zaeytijd, Julie De; Deghislage, Catherine; Frost, N A; Nijs, Ivo; Calster, Joachim Van

doi:10.1089/jop.2018.0012

Cited by 12 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another multicenter retrospective chart review of the efficacy of dexamethasone intravitreal implants for patients with persistent macular edema due to CRVO and BRVO showed that the treatment reduced central macular thickness. In addition, ocular hypertension in this study was reported in 17% of the patients ( 66 ). In a recent retrospective, consecutive series, the incidence of ocular hypertension in all patients who received intravitreal injection of 2 mg triamcinolone acetonide was reported 13.2% ( 67 ).…”

Section: Discussionsupporting

confidence: 48%

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

Jabbehdari¹,

Yazdanpanah²,

Cantor³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background and Objective: Retinal vein occlusion (RVO) is a major cause of vision loss and elevated intraocular pressure (IOP), high ocular perfusion pressure, and glaucoma are known ophthalmic risk factors for RVO. The aim of this paper is to provide the update on the association and management of high IOP/ glaucoma and RVO.Methods: A literature review was performed in PubMed and Medline until May 2022 utilizing specific keywords and cross-matched reference lists.

show abstract

Section: Discussionsupporting

confidence: 48%

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

Jabbehdari¹,

Yazdanpanah²,

Cantor³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“… Non-naive 100 71 (11.1) 49 Retrospective, single-centre 12 Rush et al [ 63 ] United States Bevacizumab (dose not specified) Three monthly injections with monthly injections until the macula is dry, then a TAE regimen. Naive 52 70.4 (12) 55.8 Retrospective, – 12 Houben et al [ 107 ] Belgium Dexamethasone 0.7 mg Single implant then PRN regimen. Non-naive 32 66.5 (12.9) 56.2 Retrospective, multi-centre 48.7 ± 30.2 weeks Ozkaya et al [ 50 ] Turkey Dexamethasone 0.7 mg Single implant then PRN regimen.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

Ang

Ah-Moye

Kim

et al. 2020

Eye

View full text Add to dashboard Cite

This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24 months. Primary outcome was change in VA (logMAR letters) at 12 months. Study quality was assessed using the quality appraisal checklist for case series developed by Institute of Health Economics. The mean baseline VA for the pooled data was 54.0 (51.5, 56.5) letters and the mean baseline CST was 501.3 (483.5, 519.1) µm. The random-effects estimate for mean (95% CI) change in VA was 14.6 (12.5, 16.7) letters at 12 months ( n = 1727). The random-effects estimate for mean (95% CI) change in CST was −181.7 (−230.7, −132.7) µm at 12 months ( n = 1325). The quality of studies varied considerably. Ocular and systemic adverse events were discussed in 79% and 42% of treatment arms respectively, with possible under-reporting. Visual and anatomical gains achieved in the real-world for anti-VEGF therapy were not as impressive as seminal RCTs, possibly due to reduced injection frequency in the real world and differences in baseline characteristics. There is an urgent need for consensus on the minimum efficacy, treatment burden and safety data to collect to strengthen the real-world evidence base.

show abstract

“…Vitrectomy does not alter the pharmacokinetics of slow-release Dexamethasone, 25 and comparisons between vitrectomized and not vitrectomized eyes demonstrated similar results in terms of macular edema reduction and BCVA improvement. 13 , 14 , 15 , 16 To the best of our knowledge, however, no study has been conducted to test whether vitrectomy could influence the frequency of macular edema recurrence in eyes treated with DEX-I.…”

Section: Discussionmentioning

confidence: 99%

“…In the last years, it has been reported that PPV does not influence the functional or anatomical efficacy of DEX-I on DME in terms of visual acuity. 13 , 14 , 15 , 16 Until now, it has not yet been analyzed if surgery may influence another interesting parameter: the duration of efficacy. This brief report aims to give contribution to filling this gap.…”

Section: Introductionmentioning

confidence: 99%

The effect of pars plana vitrectomy with internal limiting membrane peeling on the durability of the intravitreal dexamethasone implant in the treatment of diabetic macular edema

Franzolin

Gusson

Panozzo³

2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy

Cited by 12 publications

References 30 publications

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

The effect of pars plana vitrectomy with internal limiting membrane peeling on the durability of the intravitreal dexamethasone implant in the treatment of diabetic macular edema

Contact Info

Product

Resources

About